查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1933293

全球奈米醫學市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考察、未來預測（2026-2034）

Nanomedicine Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 200 Pages | 商品交期: 請詢問到貨日

價格

奈米醫學市場成長因素

2025年，全球奈米醫學（奈米藥物）市場規模為2,636.8億美元。預計該市場將從2026年的2,890.2億美元成長到2034年的7,590.9億美元，在預測期（2026-2034年）內年複合成長率（CAGR）為12.83%。

北美地區在全球奈米醫學市場佔據主導地位，到2025年佔據46.12%的市場佔有率，這主要得益於其先進的醫療基礎設施、強大的研發能力以及慢性病的高發生率。

奈米醫學是將奈米技術應用於醫學診斷、藥物傳輸和治療介入，利用尺寸介於 1 至 100 奈米之間的奈米級材料。這些技術能夠實現標靶遞送、提高生物利用度並降低全身毒性，使其在治療複雜的慢性疾病方面非常有效。奈米顆粒在製藥、診斷、生物醫學植入物、組織工程和再生醫學領域的日益廣泛應用，推動全球市場的成長。

市場概覽

受精準醫療和先進治療方案需求不斷成長的驅動，全球奈米醫學市場正經歷強勁成長。基於奈米技術的平台正用來提高藥物的溶解度、穩定性和緩釋性，進而改善患者的治療效果。奈米技術研究投入的增加、臨床試驗的增加以及奈米藥物和醫療器材獲批數量的成長，進一步鞏固了市場格局。

癌症、心血管疾病、神經退化性疾病和糖尿病等慢性疾病的日益增多，顯著提升了對標靶、微創治療的需求，使奈米醫學成為現代醫學的關鍵組成部分。

市場動態

市場驅動因素

慢性疾病盛行率上升

全球慢性疾病發生率的不斷上升是推動奈米醫學市場成長的主要因素。癌症、糖尿病、心血管疾病、神經退化性疾病和免疫相關疾病等病症需要長期、標靶的治療方法。

傳統療法常面臨療效低、脫靶毒性和生物利用度有限等挑戰。奈米醫學透過實現可控的、標靶的藥物遞送，有效應對這些挑戰，在提高療效的同時，最大限度地減少副作用。

例如，根據美國肺臟協會的資料，美國肺癌病例從2019年的221,097例增加到2023年的238,000例。這種日益加重的疾病負擔推動對基於奈米技術的診斷和標靶癌症治療的需求，支撐市場成長。

對標靶藥物遞送系統的需求不斷成長

人們越來越關注傳統藥物遞送方法的副作用，這推動了對標靶藥物遞送系統的需求。脂質體、脂質奈米顆粒、聚合物-藥物偶聯物和無機奈米顆粒等奈米載體能夠將藥物直接遞送到病變細胞，提高療效並降低全身毒性。

製藥和生物技術公司持續進行研發活動並推出先進的奈米遞送系統產品，這大幅促進了市場擴張。

市場限制因子

高成本與監理挑戰

由於需要專用設備、先進的製造流程和專業技術，奈米藥物的開發和商業化成本高昂。這些高成本可能會限制中小企業進入該領域。

此外，嚴格的監管要求，特別是安全性和毒性評估方面的要求，以及複雜的審批流程，都對市場成長構成挑戰。缺乏標準化的全球監管框架進一步加劇了審批流程的複雜性，導致產品上市延遲。

市場機會

奈米機器人在藥物傳遞與診斷的應用

奈米機器人技術在醫療領域的應用蘊藏著巨大的成長機會。奈米機器人能夠實現超精準的藥物遞送，並在細胞和分子層面上進行即時診斷。對基於奈米機器人技術的醫療解決方案的投資不斷增加，尤其是在新興市場，預計將為市場參與者創造獲利機會。

例如，2024年11月，印度公司Theranautilus籌集了120萬美元的種子資金，用於開發基於納米機器人技術的醫療器械，這凸顯了投資者對該領域日益成長的興趣。

市場挑戰

缺乏標準化的監管架構

奈米醫學市場面臨的主要挑戰之一是缺乏跨地區的標準化監管指南。這導致生產、品質控制和商業化方面存在不確定性。此外，臨床試驗的高昂成本和漫長的研發週期也構成障礙，尤其對中小企業而言更是如此。監管機構、研究人員和利害關係人之間需要通力合作，以簡化審批流程，同時確保病人安全。

最新趨勢

加速向個人化醫療轉型

個人化醫療和精準醫療正成為全球奈米醫學市場的主要趨勢。奈米技術能夠根據患者的基因、分子和表型特徵量身定制治療方案，改善療效並減少副作用。

生物製藥公司加速開發基於奈米技術的抗體藥物偶聯物（ADC）、生物標記靶向奈米顆粒和個人化藥物遞送平台。預計這些進展將在整個預測期內推動市場成長。

細分市場分析

依類型劃分

市場依類型分為治療藥物、診斷試劑和醫療器材。

受奈米藥物遞送系統在慢性病和遺傳疾病治療領域日益普及的推動，治療領域將在2026年佔據市場主導地位，市場佔有率將達到55.95%。

診斷領域將佔據第二大市場佔有率，這主要得益於對早期精準疾病診斷需求的不斷成長。

醫療器材領域預計將顯著成長，這主要得益於再生醫學和奈米塗層植入物的進步。

依顆粒類型劃分

市場依顆粒類型分為奈米顆粒、奈米殼、奈米管和奈米裝置。

預計到2026年，奈米顆粒領域將佔據最大的市場佔有率，達到76.20%，這主要得益於其在藥物遞送和診斷領域的廣泛應用。脂質和聚合物基奈米顆粒因其良好的生物相容性和穩定性而廣泛採用。由於奈米殼在標靶癌症治療領域的應用不斷擴展，預計其市場將呈現強勁成長。

依應用領域劃分

市場依應用領域細分為腫瘤學、神經退化性疾病、心血管疾病、免疫系統疾病、傳染病及其他領域。

預計到2026年，腫瘤學領域將佔據市場主導地位，市場佔有率達43.52%，這主要得益於癌症患者數量的增加和新產品的持續推出。由於基於奈米技術的腦部標靶療法的進步，神經退化性疾病領域預計將以顯著的年複合成長率成長。

依最終使用者劃分

市場依最終用戶細分為醫院和診所、診斷實驗室、研究和學術機構及其他機構。

預計到2026年，醫院和診所將以49.86%的市場佔有率引領市場，這主要得益於患者數量的成長和標靶療法的日益普及。由於對奈米醫學研發的日益重視，研究機構和學術機構預計將實現最高的成長率。

區域展望

到2025年，北美地區的市場收入達到1,216.1億美元，主要得益於FDA核准數量的增加和強勁的研發投入。

預計亞太地區將以最高的年複合成長率成長，這主要得益於臨床試驗的增加、政府資金的投入以及中國、日本和印度醫療基礎設施的不斷完善。

歐洲憑藉其先進的醫療體系和強大的研究合作，佔據了較大的市場佔有率。

預計拉丁美洲以及中東和非洲地區將保持穩定成長，這主要得益於研究網路的完善和醫療投資的增加。

這些公司致力於策略合作、收購、研發投資和產品發布，以鞏固其市場地位。

產業主要動態

  • 2023年9月：Evonik擴大其用於腸外給藥的奈米顆粒技術組合。
  • 2023年6月：BIONANOSIM與RAFARM合作成立BNS Ophthalmics。
  • 2023年3月：Moderna與Generation Bio合作開發非病毒基因治療藥物。
  • 2022年1月：Pfizer與Aquitas Therapeutics就脂質奈米顆粒遞送系統達成開發協議。

隨著癌症、心血管疾病、神經退化性疾病和傳染病等慢性疾病負擔的持續加重，對基於奈米技術的診斷和治療的需求也在不斷成長。治療藥物類別和奈米顆粒分子類型的主導地位表明，人們越來越依賴奈米平台來提高藥物療效、安全性和患者預後。此外，由於標靶癌症療法的持續創新和產品上市，腫瘤領域仍是主要的收入來源。

依地區劃分，北美憑藉強有力的監管支持、高額的研發投入和大量已獲批准的奈米藥物，保持著領先地位。同時，由於臨床試驗的增加、政府資助和不斷擴大的醫療基礎設施，亞太地區預計將實現最快的成長。歐洲則繼續受益於強大的研究合作和先進的醫療保健系統。

儘管面臨高昂的研發成本和複雜的監管等挑戰，但持續的技術創新、不斷增加的投資以及對奈米機器人和個人化醫療日益成長的關注預計將增強市場前景。主要公司的策略性舉措，包括合作、收購和新產品開發，可能會在預測期內進一步加速奈米藥物在多個治療領域的應用。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 主要國家和地區主要疾病盛行率（2025年）
  • 概述：奈米醫學在醫療領域的應用
  • 主要產業趨勢（併購、合作、新產品發表等）
  • 研發管線分析
  • 新冠疫情對全球奈米醫學的影響市場

第5章 全球奈米醫學市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依類型劃分
    • 治療藥物
      • 生物藥物
      • 小分子
    • 診斷藥
      • 體外診斷
      • 成像
      • 其他
    • 醫療器材
      • 再生醫學
      • 植入物
  • 市場分析、洞察與預測：顆粒類型
    • 奈米顆粒
      • 脂質奈米顆粒
      • 聚合物及聚合物-藥物偶聯物
      • 無機奈米顆粒
      • 其他
    • 奈米殼
    • 奈米管
    • 奈米裝置
  • 市場分析、洞察與預測：依應用領域劃分
    • 腫瘤學
    • 神經退化性疾病
    • 心血管疾病
    • 免疫疾病
    • 傳染病
    • 其他
  • 市場分析、洞察與預測：依最終用戶劃分
    • 醫院和診所
    • 診斷實驗室
    • 研究機構和學術機構
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美奈米醫學市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲奈米醫學市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 其他歐洲國家

第8章 亞太地區奈米醫學市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章 拉丁美洲奈米醫學市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第10章 中東與非洲奈米醫學市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • GCC國家
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 全球市場佔有率分析（2023）
  • 公司簡介
    • Gilead Sciences, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Jazz Pharmaceuticals plc
    • Nanospectra Biosciences, Inc.
    • Janssen Pharmaceuticals, Inc.
    • Merck &Co., Inc.
    • Amgen Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • Ipsen Pharma
Product Code: FBI110983

Growth Factors of nanomedicine Market

The global nanomedicine market size was valued at USD 263.68 billion in 2025. The market is projected to grow from USD 289.02 billion in 2026 to USD 759.09 billion by 2034, exhibiting a CAGR of 12.83% during the forecast period (2026-2034).

North America dominated the global nanomedicine market with a 46.12% market share in 2025, supported by advanced healthcare infrastructure, strong R&D capabilities, and a high prevalence of chronic diseases.

Nanomedicine involves the application of nanotechnology in medical diagnosis, drug delivery, and therapeutic interventions by utilizing nanoscale materials ranging between 1-100 nanometers. These technologies enable targeted delivery, enhanced bioavailability, and reduced systemic toxicity, making them highly effective for treating complex and chronic diseases. The expanding use of nanoparticles in pharmaceuticals, diagnostics, biomedical implants, tissue engineering, and regenerative medicine is accelerating global market growth.

MARKET OVERVIEW

The global nanomedicine market is witnessing strong growth due to increasing demand for precision medicine and advanced therapeutic solutions. Nanotechnology-based platforms are increasingly used to enhance drug solubility, stability, and controlled release, enabling improved patient outcomes. Growing investments in nanotechnology research, increasing clinical trials, and rising approvals of nano-based drugs and devices are further strengthening the market landscape.

The growing burden of chronic diseases such as cancer, cardiovascular disorders, neurodegenerative diseases, and diabetes has created substantial demand for targeted and minimally invasive treatment approaches, positioning nanomedicine as a critical component of modern healthcare.

MARKET DYNAMICS

Market Drivers

Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases globally is a major factor driving the growth of the nanomedicine market. Conditions such as cancer, diabetes, cardiovascular disorders, neurodegenerative diseases, and immune-related illnesses require long-term and targeted treatment approaches.

Traditional therapies often suffer from limitations such as poor drug efficacy, off-target toxicity, and limited bioavailability. Nanomedicine addresses these challenges by enabling controlled and site-specific drug delivery, improving therapeutic effectiveness while minimizing adverse effects.

For instance, in the United States, lung cancer cases increased from 221,097 in 2019 to 238,000 in 2023, according to the American Lung Association. This rising disease burden has increased demand for nano-based diagnostics and targeted cancer therapies, supporting market growth.

Increasing Demand for Targeted Drug Delivery Systems

The demand for targeted drug delivery systems is increasing due to rising concerns about side effects associated with conventional drug delivery. Nanocarriers such as liposomes, lipid nanoparticles, polymer-drug conjugates, and inorganic nanoparticles enable drugs to be delivered directly to diseased cells, enhancing efficacy and reducing systemic toxicity.

Continuous research and development activities, along with product launches of advanced nano-based delivery systems by pharmaceutical and biotechnology companies, are significantly contributing to market expansion.

Market Restraints

High Cost and Regulatory Challenges

The development and commercialization of nanomedicines involve high costs due to the need for specialized equipment, advanced manufacturing processes, and skilled expertise. These high costs can limit the participation of small and mid-sized companies.

Additionally, stringent regulatory requirements and complex approval pathways, particularly for safety and toxicity evaluation, pose challenges for market growth. The lack of standardized global regulatory frameworks further complicates the approval process, leading to delays in product launches.

Market Opportunities

Integration of Nanorobots for Drug Delivery and Diagnostics

The integration of nanorobotics in healthcare presents significant growth opportunities. Nanorobots enable ultra-precise drug delivery and real-time diagnostics at the cellular and molecular levels. Increasing investments in nanorobotics-based healthcare solutions, especially in emerging markets, are expected to create lucrative opportunities for market players.

For instance, in November 2024, Theranautilus (India) secured USD 1.2 million in seed funding to develop nanorobotics-based medical devices, highlighting growing investor interest in this segment.

Market Challenges

Lack of Standardized Regulatory Frameworks

One of the key challenges in the nanomedicine market is the absence of standardized regulatory guidelines across regions. This creates uncertainty in manufacturing, quality control, and commercialization. Additionally, the high cost of clinical trials and long development timelines pose barriers, particularly for smaller companies. Collaborative efforts between regulators, researchers, and industry stakeholders are required to streamline approvals while ensuring patient safety.

LATEST TRENDS

Rising Shift Toward Personalized Medicine

Personalized and precision medicine is emerging as a prominent trend in the global nanomedicine market. Nanotechnology enables the customization of therapies based on genetic, molecular, and phenotypic patient profiles, improving treatment outcomes and reducing adverse effects.

Biopharmaceutical companies are increasingly developing nano-enabled antibody-drug conjugates (ADCs), biomarker-targeted nanoparticles, and personalized drug delivery platforms. These advancements are expected to drive market growth throughout the forecast period.

SEGMENTATION ANALYSIS

By Type

Based on type, the market is segmented into therapeutics, diagnostics, and medical devices.

The therapeutics segment dominated the market with a 55.95% share in 2026, driven by increasing adoption of nano-based drug delivery systems for chronic and genetic diseases.

The diagnostics segment held the second-largest share due to rising demand for early and accurate disease diagnosis.

The medical devices segment is expected to grow substantially, supported by advancements in regenerative medicine and nano-coated implants.

By Molecule Type

The market is segmented into nanoparticles, nanoshells, nanotubes, and nanodevices.

The nanoparticles segment held the largest share of 76.20% in 2026, driven by extensive use in drug delivery and diagnostics. Lipid-based and polymer-based nanoparticles are widely adopted due to their biocompatibility and stability. Nanoshells are expected to register strong growth due to rising applications in targeted cancer therapy.

By Application

The market is categorized into oncology, neurodegenerative diseases, cardiovascular diseases, immunology, infectious diseases, and others.

The oncology segment dominated the market with a 43.52% share in 2026, supported by increasing cancer prevalence and continuous product launches. Neurodegenerative diseases are expected to grow at a significant CAGR due to advancements in nano-based brain-targeted therapies.

By End-user

Based on end-user, the market is segmented into hospitals and clinics, diagnostic laboratories, research and academic institutes, and others.

Hospitals and clinics dominated the market with a 49.86% share in 2026, driven by high patient inflow and increasing adoption of targeted therapies. Research and academic institutes are expected to register the highest growth rate due to rising focus on nanomedicine research and development.

REGIONAL OUTLOOK

North America generated USD 121.61 billion in revenue in 2025, driven by high FDA approvals and strong R&D investments.

Asia Pacific is expected to grow at the highest CAGR, supported by increasing clinical trials, government funding, and expanding healthcare infrastructure in China, Japan, and India.

Europe accounted for a substantial share due to advanced healthcare systems and strong research collaborations.

Latin America and the Middle East & Africa are expected to grow steadily, supported by improving research networks and healthcare investments.

COMPETITIVE LANDSCAPE

Key Market Players

Major companies operating in the global nanomedicine market include:

  • Pfizer Inc.
  • Janssen Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Amgen Inc.
  • Gilead Sciences, Inc.
  • Jazz Pharmaceuticals plc
  • Nanospectra Biosciences, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Ipsen Pharma

These players focus on strategic collaborations, acquisitions, R&D investments, and product launches to strengthen their market positions.

KEY INDUSTRY DEVELOPMENTS

  • September 2023 - Evonik expanded its nanoparticle technology portfolio for parenteral drug delivery
  • June 2023 - BIONANOSIM partnered with RAFARM to establish BNS Ophthalmics
  • March 2023 - Moderna collaborated with Generation Bio for non-viral genetic medicines
  • January 2022 - Pfizer entered a development agreement with Acuitas Therapeutics for lipid nanoparticle delivery systems

CONCLUSION

The global nanomedicine market is demonstrating strong and sustained growth, supported by rapid advancements in nanotechnology, increasing adoption of targeted drug delivery systems, and rising demand for precision and personalized medicine. With the market valued at USD 263.68 billion in 2025 and expected to reach USD 759.09 billion by 2034, nanomedicine is emerging as a critical pillar of next-generation healthcare solutions.

The expanding burden of chronic diseases such as cancer, cardiovascular disorders, neurodegenerative conditions, and infectious diseases continues to drive demand for nano-enabled diagnostics and therapeutics. The dominance of the therapeutics segment and nanoparticles molecule type highlights the growing reliance on nano-based platforms for improving drug efficacy, safety, and patient outcomes. Additionally, the oncology application segment remains a key revenue contributor due to continuous innovation and product launches in targeted cancer therapies.

Regionally, North America maintains its leadership position due to strong regulatory support, high R&D investments, and a large number of approved nanomedicines, while Asia Pacific is expected to witness the fastest growth owing to increasing clinical trials, government funding, and expanding healthcare infrastructure. Europe continues to benefit from robust research collaborations and advanced healthcare systems.

Despite challenges related to high development costs and regulatory complexities, ongoing technological innovations, increasing investments, and growing focus on nanorobotics and personalized medicine are expected to strengthen the market outlook. Strategic initiatives by key players, including partnerships, acquisitions, and new product developments, are likely to further accelerate the adoption of nanomedicine across multiple therapeutic areas during the forecast period.

Segmentation By Type

  • Therapeutics
    • Biologics
    • Small Molecules
  • Diagnostics
    • IVD
    • Imaging
    • Others
  • Medical Devices
    • Regenerative Medicine
    • Implants

By Molecule Type

  • Nanoparticles
    • Lipid-Based
    • Polymers & Polymer Drug Conjugates
    • Inorganic Nanoparticles
    • Others
  • Nanoshells
  • Nanotubes
  • Nanodevices

By Application

  • Oncology
  • Neurodegenerative Diseases
  • Cardiovascular Diseases
  • Immunology
  • Infectious Diseases
  • Others

By End-user

  • Hospitals and Clinics
  • Diagnostics Laboratories
  • Research and Academic Institutes
  • Others

By Geography

  • North America (By Type, By Molecule Type, By Application, By End-user, and By Country)
    • U.S.
    • Canada
  • Europe ( By Type, By Molecule Type, By Application, By End-user, and By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Type, By Molecule Type, By Application, By End-user, and By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America ( By Type, By Molecule Type, By Application, By End-user, and By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa ( By Type, By Molecule Type, By Application, By End-user, and By Country/Sub-Region)
    • GCC
    • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Disease, By Key Countries/ Regions, 2025
  • 4.2. Overview: Application of Nanomedicine in Healthcare
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches etc.)
  • 4.4. Pipeline Analysis
  • 4.5. Impact of COVID-19 on the Global Nanomedicine Market

5. Global Nanomedicine Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Therapeutics
      • 5.1.1.1. Biologics
      • 5.1.1.2. Small Molecules
    • 5.1.2. Diagnostics
      • 5.1.2.1. IVD
      • 5.1.2.2. Imaging
      • 5.1.2.3. Others
    • 5.1.3. Medical Devices
      • 5.1.3.1. Regenerative Medicine
      • 5.1.3.2. Implants
  • 5.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 5.2.1. Nanoparticles
      • 5.2.1.1. Lipid Based
      • 5.2.1.2. Polymers & Polymer Drug Conjugates
      • 5.2.1.3. Inorganic Nanoparticles
      • 5.2.1.4. Others
    • 5.2.2. Nanoshells
    • 5.2.3. Nanotubes
    • 5.2.4. Nanodevices
  • 5.3. Market Analysis, Insights and Forecast - By Application
    • 5.3.1. Oncology
    • 5.3.2. Neurodegenerative Diseases
    • 5.3.3. Cardiovascular Diseases
    • 5.3.4. Immunology
    • 5.3.5. Infectious Diseases
    • 5.3.6. Others
  • 5.4. Market Analysis, Insights and Forecast - By End-user
    • 5.4.1. Hospitals and Clinics
    • 5.4.2. Diagnostics Laboratories
    • 5.4.3. Research and Academic Institutes
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Nanomedicine Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Therapeutics
      • 6.1.1.1. Biologics
      • 6.1.1.2. Small Molecules
    • 6.1.2. Diagnostics
      • 6.1.2.1. IVD
      • 6.1.2.2. Imaging
      • 6.1.2.3. Others
    • 6.1.3. Medical Devices
      • 6.1.3.1. Regenerative Medicine
      • 6.1.3.2. Implants
  • 6.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 6.2.1. Nanoparticles
      • 6.2.1.1. Lipid Based
      • 6.2.1.2. Polymers & Polymer Drug Conjugates
      • 6.2.1.3. Inorganic Nanoparticles
      • 6.2.1.4. Others
    • 6.2.2. Nanoshells
    • 6.2.3. Nanotubes
    • 6.2.4. Nanodevices
  • 6.3. Market Analysis, Insights and Forecast - By Application
    • 6.3.1. Oncology
    • 6.3.2. Neurodegenerative Diseases
    • 6.3.3. Cardiovascular Diseases
    • 6.3.4. Immunology
    • 6.3.5. Infectious Diseases
    • 6.3.6. Others
  • 6.4. Market Analysis, Insights and Forecast - By End-user
    • 6.4.1. Hospitals and Clinics
    • 6.4.2. Diagnostics Laboratories
    • 6.4.3. Research and Academic Institutes
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Nanomedicine Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Therapeutics
      • 7.1.1.1. Biologics
      • 7.1.1.2. Small Molecules
    • 7.1.2. Diagnostics
      • 7.1.2.1. IVD
      • 7.1.2.2. Imaging
      • 7.1.2.3. Others
    • 7.1.3. Medical Devices
      • 7.1.3.1. Regenerative Medicine
      • 7.1.3.2. Implants
  • 7.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 7.2.1. Nanoparticles
      • 7.2.1.1. Lipid Based
      • 7.2.1.2. Polymers & Polymer Drug Conjugates
      • 7.2.1.3. Inorganic Nanoparticles
      • 7.2.1.4. Others
    • 7.2.2. Nanoshells
    • 7.2.3. Nanotubes
    • 7.2.4. Nanodevices
  • 7.3. Market Analysis, Insights and Forecast - By Application
    • 7.3.1. Oncology
    • 7.3.2. Neurodegenerative Diseases
    • 7.3.3. Cardiovascular Diseases
    • 7.3.4. Immunology
    • 7.3.5. Infectious Diseases
    • 7.3.6. Others
  • 7.4. Market Analysis, Insights and Forecast - By End-user
    • 7.4.1. Hospitals and Clinics
    • 7.4.2. Diagnostics Laboratories
    • 7.4.3. Research and Academic Institutes
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Nanomedicine Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Therapeutics
      • 8.1.1.1. Biologics
      • 8.1.1.2. Small Molecules
    • 8.1.2. Diagnostics
      • 8.1.2.1. IVD
      • 8.1.2.2. Imaging
      • 8.1.2.3. Others
    • 8.1.3. Medical Devices
      • 8.1.3.1. Regenerative Medicine
      • 8.1.3.2. Implants
  • 8.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 8.2.1. Nanoparticles
      • 8.2.1.1. Lipid Based
      • 8.2.1.2. Polymers & Polymer Drug Conjugates
      • 8.2.1.3. Inorganic Nanoparticles
      • 8.2.1.4. Others
    • 8.2.2. Nanoshells
    • 8.2.3. Nanotubes
    • 8.2.4. Nanodevices
  • 8.3. Market Analysis, Insights and Forecast - By Application
    • 8.3.1. Oncology
    • 8.3.2. Neurodegenerative Diseases
    • 8.3.3. Cardiovascular Diseases
    • 8.3.4. Immunology
    • 8.3.5. Infectious Diseases
    • 8.3.6. Others
  • 8.4. Market Analysis, Insights and Forecast - By End-user
    • 8.4.1. Hospitals and Clinics
    • 8.4.2. Diagnostics Laboratories
    • 8.4.3. Research and Academic Institutes
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Nanomedicine Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Therapeutics
      • 9.1.1.1. Biologics
      • 9.1.1.2. Small Molecules
    • 9.1.2. Diagnostics
      • 9.1.2.1. IVD
      • 9.1.2.2. Imaging
      • 9.1.2.3. Others
    • 9.1.3. Medical Devices
      • 9.1.3.1. Regenerative Medicine
      • 9.1.3.2. Implants
  • 9.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 9.2.1. Nanoparticles
      • 9.2.1.1. Lipid Based
      • 9.2.1.2. Polymers & Polymer Drug Conjugates
      • 9.2.1.3. Inorganic Nanoparticles
      • 9.2.1.4. Others
    • 9.2.2. Nanoshells
    • 9.2.3. Nanotubes
    • 9.2.4. Nanodevices
  • 9.3. Market Analysis, Insights and Forecast - By Application
    • 9.3.1. Oncology
    • 9.3.2. Neurodegenerative Diseases
    • 9.3.3. Cardiovascular Diseases
    • 9.3.4. Immunology
    • 9.3.5. Infectious Diseases
    • 9.3.6. Others
  • 9.4. Market Analysis, Insights and Forecast - By End-user
    • 9.4.1. Hospitals and Clinics
    • 9.4.2. Diagnostics Laboratories
    • 9.4.3. Research and Academic Institutes
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Nanomedicine Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Therapeutics
      • 10.1.1.1. Biologics
      • 10.1.1.2. Small Molecules
    • 10.1.2. Diagnostics
      • 10.1.2.1. IVD
      • 10.1.2.2. Imaging
      • 10.1.2.3. Others
    • 10.1.3. Medical Devices
      • 10.1.3.1. Regenerative Medicine
      • 10.1.3.2. Implants
  • 10.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 10.2.1. Nanoparticles
      • 10.2.1.1. Lipid Based
      • 10.2.1.2. Polymers & Polymer Drug Conjugates
      • 10.2.1.3. Inorganic Nanoparticles
      • 10.2.1.4. Others
    • 10.2.2. Nanoshells
    • 10.2.3. Nanotubes
    • 10.2.4. Nanodevices
  • 10.3. Market Analysis, Insights and Forecast - By Application
    • 10.3.1. Oncology
    • 10.3.2. Neurodegenerative Diseases
    • 10.3.3. Cardiovascular Diseases
    • 10.3.4. Immunology
    • 10.3.5. Infectious Diseases
    • 10.3.6. Others
  • 10.4. Market Analysis, Insights and Forecast - By End-user
    • 10.4.1. Hospitals and Clinics
    • 10.4.2. Diagnostics Laboratories
    • 10.4.3. Research and Academic Institutes
    • 10.4.4. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2023)
  • 11.2. Company Profiles
    • 11.2.1. Gilead Sciences, Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Teva Pharmaceutical Industries Ltd.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Pfizer Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Jazz Pharmaceuticals plc
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Nanospectra Biosciences, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Janssen Pharmaceuticals, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Merck & Co., Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Amgen Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Arrowhead Pharmaceuticals, Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Ipsen Pharma
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Nanomedicine Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Nanomedicine Market Revenue (USD billion) Forecast, by Therapeutics, 2021-2034
  • Table 3: Global Nanomedicine Market Revenue (USD billion) Forecast, by Diagnostics, 2021-2034
  • Table 4: Global Nanomedicine Market Revenue (USD billion) Forecast, by Medical Devices, 2021-2034
  • Table 5: Global Nanomedicine Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 6: Global Nanomedicine Market Revenue (USD billion) Forecast, by Nanoparticles, 2021-2034
  • Table 7: Global Nanomedicine Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 8: Global Nanomedicine Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 9: Global Nanomedicine Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 10: North America Nanomedicine Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 11: North America Nanomedicine Market Revenue (USD billion) Forecast, by Therapeutics, 2021-2034
  • Table 12: North America Nanomedicine Market Revenue (USD billion) Forecast, by Diagnostics, 2021-2034
  • Table 13: North America Nanomedicine Market Revenue (USD billion) Forecast, by Medical Devices, 2021-2034
  • Table 14: North America Nanomedicine Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 15: North America Nanomedicine Market Revenue (USD billion) Forecast, by Nanoparticles, 2021-2034
  • Table 16: North America Nanomedicine Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 17: North America Nanomedicine Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 18: North America Nanomedicine Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 19: Europe Nanomedicine Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 20: Europe Nanomedicine Market Revenue (USD billion) Forecast, by Therapeutics, 2021-2034
  • Table 21: Europe Nanomedicine Market Revenue (USD billion) Forecast, by Diagnostics, 2021-2034
  • Table 22: Europe Nanomedicine Market Revenue (USD billion) Forecast, by Medical Devices, 2021-2034
  • Table 23: Europe Nanomedicine Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 24: Europe Nanomedicine Market Revenue (USD billion) Forecast, by Nanoparticles, 2021-2034
  • Table 25: Europe Nanomedicine Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 26: Europe Nanomedicine Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 27: Europe Nanomedicine Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 28: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 29: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by Therapeutics, 2021-2034
  • Table 30: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by Diagnostics, 2021-2034
  • Table 31: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by Medical Devices, 2021-2034
  • Table 32: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 33: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by Nanoparticles, 2021-2034
  • Table 34: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 35: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 36: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 37: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 38: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by Therapeutics, 2021-2034
  • Table 39: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by Diagnostics, 2021-2034
  • Table 40: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by Medical Devices, 2021-2034
  • Table 41: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 42: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by Nanoparticles, 2021-2034
  • Table 43: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 44: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 45: Latin America Nanomedicine Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 46: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 47: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by Therapeutics, 2021-2034
  • Table 48: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by Diagnostics, 2021-2034
  • Table 49: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by Medical Devices, 2021-2034
  • Table 50: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 51: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by Nanoparticles, 2021-2034
  • Table 52: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 53: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 54: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Nanomedicine Market Revenue Breakdown (USD billion, %) by Region, 2023 & 2034
  • Figure 2: Global Nanomedicine Market Value Share (%), by Type, 2023 & 2034
  • Figure 3: Global Nanomedicine Market Value Share (%), by Molecule Type, 2023 & 2034
  • Figure 4: Global Nanomedicine Market Value Share (%), by Application, 2023 & 2034
  • Figure 5: Global Nanomedicine Market Value Share (%), by End-user, 2023 & 2034
  • Figure 6: Global Nanomedicine Market Value (USD billion), by Region, 2023 & 2034
  • Figure 7: North America Nanomedicine Market Value (USD billion), by Type, 2023 & 2034
  • Figure 8: North America Nanomedicine Market Value Share (%), by Type, 2023
  • Figure 9: North America Nanomedicine Market Value (USD billion), by Molecule Type, 2023 & 2034
  • Figure 10: North America Nanomedicine Market Value Share (%), by Molecule Type, 2023
  • Figure 11: North America Nanomedicine Market Value (USD billion), by Application, 2023 & 2034
  • Figure 12: North America Nanomedicine Market Value Share (%), by Application, 2023
  • Figure 13: North America Nanomedicine Market Value (USD billion), by End-user, 2023 & 2034
  • Figure 14: North America Nanomedicine Market Value Share (%), by End-user, 2023
  • Figure 15: North America Nanomedicine Market Value (USD billion), By Country, 2023 & 2034
  • Figure 16: North America Nanomedicine Market Value Share (%), By Country, 2023
  • Figure 17: Europe Nanomedicine Market Value (USD billion), by Type, 2023 & 2034
  • Figure 18: Europe Nanomedicine Market Value Share (%), by Type, 2023
  • Figure 19: Europe Nanomedicine Market Value (USD billion), by Molecule Type, 2023 & 2034
  • Figure 20: Europe Nanomedicine Market Value Share (%), by Molecule Type, 2023
  • Figure 21: Europe Nanomedicine Market Value (USD billion), by Application, 2023 & 2034
  • Figure 22: Europe Nanomedicine Market Value Share (%), by Application, 2023
  • Figure 23: Europe Nanomedicine Market Value (USD billion), by End-user, 2023 & 2034
  • Figure 24: Europe Nanomedicine Market Value Share (%), by End-user, 2023
  • Figure 25: Europe Nanomedicine Market Value (USD billion), By Country/ Sub-region, 2023 & 2034
  • Figure 26: Europe Nanomedicine Market Value Share (%), By Country/ Sub-region, 2023
  • Figure 27: Asia Pacific Nanomedicine Market Value (USD billion), by Type, 2023 & 2034
  • Figure 28: Asia Pacific Nanomedicine Market Value Share (%), by Type, 2023
  • Figure 29: Asia Pacific Nanomedicine Market Value (USD billion), by Molecule Type, 2023 & 2034
  • Figure 30: Asia Pacific Nanomedicine Market Value Share (%), by Molecule Type, 2023
  • Figure 31: Asia Pacific Nanomedicine Market Value (USD billion),by Application, 2023 & 2034
  • Figure 32: Asia Pacific Nanomedicine Market Value Share (%), by Application, 2023
  • Figure 33: Asia Pacific Nanomedicine Market Value (USD billion), by End-user, 2023 & 2034
  • Figure 34: Asia Pacific Nanomedicine Market Value Share (%), by End-user, 2023
  • Figure 35: Asia Pacific Nanomedicine Market Value (USD billion), By Country/ Sub-region, 2023 & 2034
  • Figure 36: Asia Pacific Nanomedicine Market Value Share (%), By Country/ Sub-region, 2023
  • Figure 37: Latin America Nanomedicine Market Value (USD billion), by Type, 2023 & 2034
  • Figure 38: Latin America Nanomedicine Market Value Share (%), by Type, 2023
  • Figure 39: Latin America Nanomedicine Market Value (USD billion), by Molecule Type, 2023 & 2034
  • Figure 40: Latin America Nanomedicine Market Value Share (%), by Molecule Type, 2023
  • Figure 41: Latin America Nanomedicine Market Value (USD billion), by Application, 2023 & 2034
  • Figure 42: Latin America Nanomedicine Market Value Share (%), by Application, 2023
  • Figure 43: Latin America Nanomedicine Market Value (USD billion), by End-user, 2023 & 2034
  • Figure 44: Latin America Nanomedicine Market Value Share (%), by End-user, 2023
  • Figure 45: Latin America Nanomedicine Market Value (USD billion), By Country/ Sub-region, 2023 & 2034
  • Figure 46: Latin America Nanomedicine Market Value Share (%), By Country/ Sub-region, 2023
  • Figure 47: Middle East & Africa Nanomedicine Market Value (USD billion), by Type, 2023 & 2034
  • Figure 48: Middle East & Africa Nanomedicine Market Value Share (%), by Type, 2023
  • Figure 49: Middle East & Africa Nanomedicine Market Value (USD billion), by Molecule Type, 2023 & 2034
  • Figure 50: Middle East & Africa Nanomedicine Market Value Share (%), by Molecule Type, 2023
  • Figure 51: Middle East & Africa Nanomedicine Market Value (USD billion), by Application, 2023 & 2034
  • Figure 52: Middle East & Africa Nanomedicine Market Value Share (%), by Application, 2023
  • Figure 53: Middle East & Africa Nanomedicine Market Value (USD billion), by End-user, 2023 & 2034
  • Figure 54: Middle East & Africa Nanomedicine Market Value Share (%), by End-user, 2023
  • Figure 55: Middle East & Africa Nanomedicine Market Value (USD billion), By Country/ Sub-region, 2023 & 2034
  • Figure 56: Middle East & Africa Nanomedicine Market Value Share (%), By Country/ Sub-region, 2023
  • Figure 57: Global Nanomedicine Market Share (%), By Company, 2023